Emerging research challenges the long-held belief that amyloid plaques are the sole culprits in Alzheimer's disease. Instead, a novel hypothesis posits that a molecular switch, ERBB4, when aberrantly activated in specific neurons, may be a central orchestrator of diverse Alzheimer's pathologies. This misdirected signal appears to initiate a cascade of detrimental events, including the disruption of neural circuits, the eradication of synapses, the activation of glial cells, heightened amyloid accumulation, and ultimately, cognitive decline.
Scientists have grappled with explaining the simultaneous onset and progression of various Alzheimer's abnormalities, such as synaptic loss, neural circuit instability, reactive gliosis, amyloid plaque formation, and cognitive decline. This new perspective, focusing on ERBB4's role, offers a unifying explanation for these seemingly disparate symptoms, suggesting a more complex and interconnected pathological process than previously understood. Understanding this molecular switch could unlock new avenues for therapeutic intervention, potentially targeting multiple aspects of the disease simultaneously.
ERBB4's Unanticipated Role in Neuronal Dysfunction and Alzheimer's Progression
A recent study, led by Associate Director CHUNG Won-Suk at the Institute for Basic Science (IBS), has highlighted the aberrant expression of ERBB4 in excitatory neurons as a pivotal, early trigger for a multitude of Alzheimer's disease pathologies. While ERBB4 is typically associated with inhibitory neurons, its appearance in excitatory neurons appears to initiate a series of detrimental effects within the brain. This mislocalization leads to neuronal hyperactivity, the abnormal loss of synapses—the critical communication points between neurons—and the activation of glial cells, which are normally supportive but become reactive in disease states. Furthermore, this aberrant ERBB4 activity contributes to the accumulation of amyloid, a hallmark of Alzheimer's, and ultimately results in cognitive impairment.
Initially, the research team focused on glial cells, specifically astrocytes and microglia, known for their roles in supporting and protecting brain health, including the removal of unnecessary synapses. The expectation was that these cells might become overactive in Alzheimer's, leading to excessive synaptic destruction. However, the findings revealed a more nuanced picture. In mouse models of Alzheimer's, glial cells were found to selectively engulf excitatory synapses while sparing inhibitory ones. This selective pruning, rather than a generalized increase in glial activity, suggested a directed response to abnormal neuronal signals. When neuronal activity was artificially increased, glial engulfment of synapses also rose, and conversely, when activity was suppressed, engulfment decreased. This indicated that glial cells were not acting autonomously but were reacting to dysfunctional signals originating from neurons, prompting a deeper investigation into the underlying neuronal mechanisms.
Targeting ERBB4: A Potential New Therapeutic Strategy
The discovery that ERBB4, a receptor primarily found in inhibitory neurons, was aberrantly activated in excitatory neurons in Alzheimer's disease models prompted a critical question: was ERBB4 merely an indicator of the disease, or an active contributor to its progression? To address this, researchers utilized targeted gene editing to selectively remove Erbb4 from hippocampal excitatory neurons in mouse models of Alzheimer's. The results were profound and far-reaching, demonstrating that reducing ERBB4 expression mitigated neuronal hyperactivity, restored balance to inhibitory circuit activity, and corrected abnormal synaptic changes. Crucially, this intervention also reduced reactive changes in astrocytes and microglia, decreased the burden of amyloid plaques, and improved performance in memory and spatial cognition tests. The beneficial effects were sustained over time, and even late-stage intervention showed positive outcomes, suggesting ERBB4's pivotal role in driving the disease's multifaceted pathologies.
Conversely, activating ERBB4 in a subset of excitatory neurons in otherwise healthy mice mirrored many aspects of Alzheimer's, including circuit hyperactivity, synaptic imbalance, reactive gliosis, and cognitive deficits, even in the absence of amyloid plaques. These experiments strongly suggest that abnormal ERBB4 expression is not merely a consequence of Alzheimer's but an active driver of its pathology. Further investigation identified mTOR signaling as a key pathway through which ERBB4 exerts its effects, positioning the ERBB4-mTOR axis as a crucial control point linking neuronal hyperactivity with synaptic, glial, and cognitive abnormalities. While human data from postmortem brain samples and transcriptomic analyses support the relevance of these findings to human Alzheimer's, further research is needed to determine if ERBB4 directly causes the disease in people. Nevertheless, targeting ERBB4 represents a promising therapeutic strategy, potentially influencing multiple pathological processes simultaneously, offering a novel approach to combat this complex neurodegenerative disorder.